Researcher Next
Create account
← Back to directory

Gilberto de Castro

Researcher Next ID · RN-029146

Researcher · Medicine

Eastern Cooperative Oncology Group

Philadelphia, Brazil

Sign in to saveSign in to claim
Not currently recruitingFunding unknown
Works count
468
Citation count
32,042
H-index
55
i10-index
147

Research interests

Medicine
Cancer Immunotherapy and Biomarkers
Lung Cancer Treatments and Mutations
Head and Neck Cancer Studies
Lung Cancer Diagnosis and Treatment
Lung Cancer Research Studies

Publications

  • Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

    Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.23.02747

  • Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

    Journal of Clinical Oncology · 2022 · https://doi.org/10.1200/jco.21.02508

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32591-7

  • Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

    The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(18)32409-7

  • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

    The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(16)32616-2

  • First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

    The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)30123-x

  • Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

    The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)70124-5

  • Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

    The Lancet · 2015 · 10.1016/s0140-6736(15)01281-7

  • Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients

    British Journal of Cancer · 2007 · https://doi.org/10.1038/sj.bjc.6603756

Current projects

    No projects listed.